Similar articles

• [Treatment of congenital insufficiency in fibrin stabilising factor (FSF or factor XIII) by purified factor XIII of placental origin. Report of two cases with a four year follow up].

  Caille B, Vergoz D, Vie JC, Braive JP, Capron F, Duriez S, Sarrade-Loucheur C, Ferrer F. Caille B, et al. Ann Pediatr (Paris). 1977 Dec;24(12):837-42. Ann Pediatr (Paris). 1977. PMID: 16218265 French. No abstract available.
• Clinical experience with a pasteurised human plasma concentrate in factor XIII deficiency.

  Daly HM, Haddon ME. Daly HM, et al. Thromb Haemost. 1988 Apr 8;59(2):171-4. Thromb Haemost. 1988. PMID: 3388293
• Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.

  Nugent DJ, Ashley C, García-Talavera J, Lo LC, Mehdi AS, Mangione A. Nugent DJ, et al. Haemophilia. 2015 Jan;21(1):95-101. doi: 10.1111/hae.12505. Epub 2014 Dec 2. Haemophilia. 2015. PMID: 25458735
• Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.

  Tahlan A, Ahluwalia J. Tahlan A, et al. Arch Pathol Lab Med. 2014 Feb;138(2):278-81. doi: 10.5858/arpa.2012-0639-RS. Arch Pathol Lab Med. 2014. PMID: 24476525 Review.
• Prophylaxis in rare coagulation disorders -- factor XIII deficiency.

  Nugent DJ. Nugent DJ. Thromb Res. 2006;118 Suppl 1:S23-8. doi: 10.1016/j.thromres.2006.02.009. Epub 2006 Apr 17. Thromb Res. 2006. PMID: 16616323 Review.